Important Information

This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:

  • You will not be guaranteed Negative Balance Protection
  • You will not be protected by FCA’s leverage restrictions
  • You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
  • You will not be protected by Financial Services Compensation Scheme (FSCS)
  • Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.

Note: Ultima Markets is currently developing a dedicated website for UK clients and expects to onboard UK clients under FCA regulations in 2026.

If you would like to proceed and visit this website, you acknowledge and confirm the following:

  • 1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
  • 2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
  • 3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
  • 4.Investing through this website does not grant you the protections provided by the FCA.
  • 5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.

Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.

By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.

I confirm my intention to proceed and enter this website

Tag Archives: Novo Nordisk

減肥及糖尿病藥物熱銷 諾和諾德上修展望 

丹麥製藥公司Novo Nordisk諾和諾德 (NVO) 最近因其減重藥Wegovy和糖尿病藥物Ozempic的需求增加,上修其年度財務展望。這些藥物是通過每週注射給予,並且因其顯著的減重效果而受到患者的追捧。  諾和諾德上修財測  Novo Nordisk 表示,銷售增長將在32%到38%之間,高於先前的27%到33%的估計。該公司還預計營業利潤增長將達到40%至46%,高於先前的31%至37%的預測。樂觀的展望主要是由於Ozempic在美國市場的銷售超出預期。  諾和諾德股價創今年新高  Wegovy和Ozempic的受歡迎程度使Novo Nordisk成為歐洲最有價值的公司。該公司在美國上市的ADR股票也創下了今年的新高。Novo Nordisk將於11月2日公佈其第三季度盈利。  NVO宣佈13億美元收購  Novo Nordisk將支付高達13億美元予KBP Biosciences購買新藥Ocurenone。  該藥物可以幫助那些難以控制高血壓的病人。購買新藥的交易將在今年年底完成,並不會影響該公司今年的利潤。  (Novo Nordisk ADR 年初至今表現)  免責聲明  本文所含評論、新聞、研究、分析、價格及其他資料只能視作一般市場資訊,僅為協助讀者瞭解市場形勢而提供,並不構成投資建議。Ultima Markets已採取合理措施確保資料的準確性,但不能保證資料的精確度,及可隨時更改而毋須作出通知。Ultima Markets不會為直接或間接使用或依賴此等資料而可能引致的任何虧損或損失(包括但不限於任何盈利的損失)負責。